News Atlas closes $450m biotech fund, and other financing news Atlas Venture raised $450m for its fourteenth biotech round, while Nuvig, Maze, and Antag also closed financings this week.
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
